Dynavax Technologies Corp. (DVAX) rose 39%, marking its best intraday performance in the last four years, following the company's agreement with Sanofi

Berenberg Bank Sticks to Their Buy Rating for Sanofi (SNYNF)

Berenberg Bank's Luisa Hector maintained a Buy rating for Sanofi with a price target of €105.00. Hector, who covers the Healthcare sector, has an average return of 6.3% and a 62.50% success rate. Deutsche Bank also rated Sanofi as Buy, while Kepler Capital maintained a Hold rating.

The CAC 40 Index Opens 0.19% Higher

The CAC 40 Index is gaining 15 points or 0.19 percent on Thursday.Leading the gains are Eurofins Scientific SE (1.05%), Sanofi (0.94%) and Safran (0.85%).Top losers are Stellantis NV (-1.31%), Kering (-1.27%) and Renault (-0.98%).

Key facts: Sanofi's Efdoralprin Alfa gains orphan status; $7.5M to Cytokinetics; rejects most-favored-nation pricing

Sanofi's Efdoralprin Alfa gained orphan status from the EMA for treating emphysema linked to Alpha-1 Antitrypsin Deficiency, meeting all Phase 2 study endpoints. Data will be presented soon.1Sanofi will pay $7.5 million to Cytokinetics following the approval of Myqorzo for obstructive hypertrophic cardiomyopathy in China, where Sanofi holds exclusive rights.2Sanofi has not accepted the most-favored-nation pricing for drugs, aligning with eleven other pharma firms, while Pfizer, Eli Lilly, AstraZeneca, Novo Nordisk, and EMD Serono have agreed.3

TD Cowen Reaffirms Their Hold Rating on Sanofi (SNY)

TD Cowen analyst Steve Scala maintains a Hold rating on Sanofi with a price target of $57.00. Scala, a 4-star analyst, has an average return of 11.0% and a 64.82% success rate. The analyst consensus on Sanofi is a Moderate Buy with an average price target of $63.00.